GRFS (Grifols) Short-Term Debt : $2,765 Mil (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Grifols Short-Term Debt?

Grifols's Short-Term Debt for the quarter that ended in Jun. 2024 was $2,765 Mil.

Grifols's quarterly Short-Term Debt increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($862 Mil) and increased from Dec. 2023 ($862 Mil) to Jun. 2024 ($2,765 Mil).

Grifols's annual Short-Term Debt declined from Dec. 2021 ($2,650 Mil) to Dec. 2022 ($613 Mil) but then increased from Dec. 2022 ($613 Mil) to Dec. 2023 ($862 Mil).

Grifols Short-Term Debt Historical Data

The historical data trend for Grifols's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Short-Term Debt Chart

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

307.11

336.90

2,650.41

613.26

862.39

Grifols Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24
Short-Term Debt	Get a 7-Day Free Trial															613.26	-	-	862.39	2,765.18

Grifols Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Grifols Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Grifols's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.